Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
The Journal of Infectious Diseases
|
January 12, 2018
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
Youyi Fong, Xiaoying Shen, Vicki C Ashley, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
The Lancet. HIV
|
June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
Linda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Nature Communications
|
January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications
|
March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Science (New York, N.Y.)
|
November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
The Journal of Infectious Diseases
|
January 12, 2018
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
Youyi Fong, Xiaoying Shen, Vicki C Ashley, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
The Lancet. HIV
|
June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
Linda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Nature Communications
|
January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications
|
March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Science (New York, N.Y.)
|
November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
Page
of 8